Exelixis Inc Income (Loss) Attributable to Noncontrolling Interest, before Tax
Exelixis Inc (EXEL) reported Income (Loss) Attributable to Noncontrolling Interest, before Tax of -$4.34 million for the 12-month period ending 2009-12-31, per its 10-K filed 2012-02-22.
Discontinued › Expense Statement › Operating Expenses
us-gaap:IncomeLossAttributableToNoncontrollingInterest · last filed 2012-02-22
- Exelixis Inc income (loss) attributable to noncontrolling interest, before tax for fiscal 2009 was -$4.34M, a 719.57% decline from fiscal 2008.
- Exelixis Inc income (loss) attributable to noncontrolling interest, before tax for fiscal 2008 was $700.00K.
| Period end | Income (Loss) Attributable to Noncontrolling Interest, before Tax 12 month |
|---|---|
| 2009-12-31 | -$4.34M 10-K · filed 2012-02-22 |
| 2008-12-31 | $700.00K 10-K · filed 2012-02-22 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |
| Krystal Biotech, Inc. (KRYS) | United States | $10.210B | 45.56 |
| Kymera Therapeutics, Inc. (KYMR) | United States | $9.631B | -31.69 |
| ImmunityBio, Inc. (IBRX) | United States | $9.157B | -9.29 |
| Vaxcyte, Inc. (PCVX) | United States | $8.466B | -7.91 |
| Immunovant, Inc. (IMVT) | United States | $7.028B | -14.78 |